iTeos Therapeutics (ITOS) to Wind Down Operations

iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the intention to wind down its operations as part of a comprehensive review of strategic alternatives aimed at maximizing shareholder value.

Following a thorough assessment of the Company’s development pipeline, business prospects, and financial position, the Company’s Board of Directors intends to wind down clinical and operational activities and focus on leveraging the Company’s cash balance to deliver near-term value to shareholders, including any proceeds from the potential sale of the Company’s intellectual property and assets such as EOS-984, EOS-215, and a preclinical obesity program targeting ENT1.

You May Also Be Interested In

• Trex (TREX) Reiterated at Hold by Benchmark as Partnership Agreement Announced
• HCA Healthcare cuts 2026 profit outlook on insurance exchange losses
• Microchip releases free VectorBlox 3.0 SDK for FPGA-based AI